Vahid Sebghatollahi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vahid Sebghatollahi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Shavakhi
Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications- Ali Akbar Shayesteh
Alimentary Tract Research Center, Clinical Sciences Research Institute, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 shared publications Mahsa Khodadoostan
Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publicationsMohammad Minakari
Department of Internal Medicine, Division of Gastroenterology, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications- Eskandar Hajiani
Ahvaz Jundishapur University of Medical Sciences, Iran
2 shared publications - Pezhman Alavinejad
Alimentary Tract Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 shared publications
Latest Publications
- Open Access
- 6 August 2025
- Published byĀ Maad Rayan Publishing CompanyĀ inĀ Journal of Advanced Periodontology & Implant Dentistry
- Vol.Ā 17 Ā (3) , 145-151
Effect of nonsurgical periodontal therapy on the eradication of gastric Helicobacter pylori infection: A randomized clinical trial
Background. This study aimed to assess the effectiveness of "a combined systemic and nonsurgical periodontal treatment" in eradicating gastric Helicobacter pylori in patients having the bacterium within their subgingival biofilm. Methods. This randomized clinical trial (RCT) investigated 102 patients diagnosed with peptic ulcer or dyspepsia and a positive stomach test for H. pylori infection (G+). Participants with a negative test for oral infection received only triple therapy (G3, n=38), and those positive for oral infection were randomly allocated to one of the two treatment regimens: a 14-day course of triple therapy (comprising antibiotics, antimicrobials, and proton pump inhibitors) alongside periodontal therapy (G1, n=32) or triple therapy alone (G2, n=32). The effectiveness of H. pylori eradication was assessed four weeks after treatment using the H. pylori stool antigen (stool Ag) test. Data analysis was performed using SPSS 22. Results. In the G2 and G3 groups, triple therapy achieved success rates of 52% and 84%, respectively. When periodontal therapy was integrated with triple therapy in the G1 group, the success rate was 80%. Significant differences were observed between the G1 and G2 groups (P=0.037) and also between the G3 and G2 groups (P=0.015). Conversely, no significant difference was found between the G1 and G3 groups (P>0.05). Conclusion. Periodontal therapy has the potential to substantially increase the efficacy of H. pylori eradication regimens for gastric infections.
- 6 August 2025
- Published byĀ Maad Rayan Publishing CompanyĀ inĀ Journal of Advanced Periodontology & Implant Dentistry
- Vol.Ā 17 Ā (3) , 145-151
Open AccessEffect of nonsurgical periodontal therapy on the eradication of gastric Helicobacter pylori infection: A randomized clinical trial
Background. This study aimed to assess the effectiveness of "a combined systemic and nonsurgical periodontal treatment" in eradicating gastric Helicobacter pylori in patients having the bacterium within their subgingival biofilm. Methods. This randomized clinical trial (RCT) investigated 102 patients diagnosed with peptic ulcer or dyspepsia and a positive stomach test for H. pylori infection (G+). Participants with a negative test for oral infection received only triple therapy (G3, n=38), and those positive for oral infection were randomly allocated to one of the two treatment regimens: a 14-day course of triple therapy (comprising antibiotics, antimicrobials, and proton pump inhibitors) alongside periodontal therapy (G1, n=32) or triple therapy alone (G2, n=32). The effectiveness of H. pylori eradication was assessed four weeks after treatment using the H. pylori stool antigen (stool Ag) test. Data analysis was performed using SPSS 22. Results. In the G2 and G3 groups, triple therapy achieved success rates of 52% and 84%, respectively. When periodontal therapy was integrated with triple therapy in the G1 group, the success rate was 80%. Significant differences were observed between the G1 and G2 groups (P=0.037) and also between the G3 and G2 groups (P=0.015). Conversely, no significant difference was found between the G1 and G3 groups (P>0.05). Conclusion. Periodontal therapy has the potential to substantially increase the efficacy of H. pylori eradication regimens for gastric infections.
- Open Access
- 26 August 2022
- Published byĀ WileyĀ inĀ Clinical Case Reports
- Vol.Ā 10 Ā (8) , e6247
Hyponatremiaāinduced generalized seizure after taking polyethylene glycol for colon preparationāA case report and brief review of the literature
Severe hyponatremia is lifeāthreatening in hospitalized patients. We present an elderly female who developed severe hyponatremia, seizure, and loss of consciousness after taking polyethylene glycol (PEG) solution before colonoscopy. The risk of hyponatremia with PEG for colon preparation in elderly susceptible patients is high. We review the relevant literature.
- 26 August 2022
- Published byĀ WileyĀ inĀ Clinical Case Reports
- Vol.Ā 10 Ā (8) , e6247
Open AccessHyponatremiaāinduced generalized seizure after taking polyethylene glycol for colon preparationāA case report and brief review of the literature
Severe hyponatremia is lifeāthreatening in hospitalized patients. We present an elderly female who developed severe hyponatremia, seizure, and loss of consciousness after taking polyethylene glycol (PEG) solution before colonoscopy. The risk of hyponatremia with PEG for colon preparation in elderly susceptible patients is high. We review the relevant literature.
- Open Access
- 1 January 2018
- Published byĀ MedknowĀ inĀ Journal of Research in Medical Sciences
- Vol.Ā 23 Ā (1) , 54
Serum amylase and lipase levels for prediction of postendoscopic retrograde cholangiopancreatography pancreatitis
Background: The aim of the present study was to assess 2- and 4-h postendoscopic retrograde cholangiopancreatography (ERCP) serum amylase and lipase levels for prediction of post-ERCP, pancreatitis (PEP), and their predictive cutoff values. Materials and Methods: In this cross-sectional study, we evaluated serum amylase and lipase levels before the procedure, 2 h and 4 h after the procedure, and in patients with persisting abdominal pain, 24 h afterward. A total of 300 adult patients who underwent ERCP procedures from March 2014 to June 2015 in referral hospital in Isfahan were studied. The receiver operating characteristic analysis was applied to determine the predictive score of amylase and lipase levels for PEP 2 and 4 h after ERCP. Results: The 2-h serum amylase cutoff values of 241 IU/L (normal range: 28ā100 IU/L) had a very high negative predictive value (NPV) (98.7%) but a poor positive predictive value (49.2%) for prediction of PEP (area under curve [AUC]: 0.947; 95% confidence interval [CI]: 0.914ā0.979). Based on our results, the patients might be considered for supportive therapy of PEP with the 4-h serum amylase above the cut point of 839.5 IU/L with a specificity of 95.1% (AUC: 0.978; 95% CI: 0.964ā0.992). In addition, the 2- and 4-h serum lipase levels at cut points of 216 IU/L (AUC: 0.954; 95% CI: 0.931ā0.977) and 656.5 IU/L (AUC: 0.966; 95% CI: 0.945ā0.986) (normal value <60 IU/L), respectively, had the best sensitivity (97.1%) and high NPVs (99.6%) for exclusion of PEP. Conclusion: Measurements of serum amylase and lipase 2- and 4-h post-ERCP might be useful in prediction of PEP.
- 1 January 2018
- Published byĀ MedknowĀ inĀ Journal of Research in Medical Sciences
- Vol.Ā 23 Ā (1) , 54
Open AccessSerum amylase and lipase levels for prediction of postendoscopic retrograde cholangiopancreatography pancreatitis
Background: The aim of the present study was to assess 2- and 4-h postendoscopic retrograde cholangiopancreatography (ERCP) serum amylase and lipase levels for prediction of post-ERCP, pancreatitis (PEP), and their predictive cutoff values. Materials and Methods: In this cross-sectional study, we evaluated serum amylase and lipase levels before the procedure, 2 h and 4 h after the procedure, and in patients with persisting abdominal pain, 24 h afterward. A total of 300 adult patients who underwent ERCP procedures from March 2014 to June 2015 in referral hospital in Isfahan were studied. The receiver operating characteristic analysis was applied to determine the predictive score of amylase and lipase levels for PEP 2 and 4 h after ERCP. Results: The 2-h serum amylase cutoff values of 241 IU/L (normal range: 28ā100 IU/L) had a very high negative predictive value (NPV) (98.7%) but a poor positive predictive value (49.2%) for prediction of PEP (area under curve [AUC]: 0.947; 95% confidence interval [CI]: 0.914ā0.979). Based on our results, the patients might be considered for supportive therapy of PEP with the 4-h serum amylase above the cut point of 839.5 IU/L with a specificity of 95.1% (AUC: 0.978; 95% CI: 0.964ā0.992). In addition, the 2- and 4-h serum lipase levels at cut points of 216 IU/L (AUC: 0.954; 95% CI: 0.931ā0.977) and 656.5 IU/L (AUC: 0.966; 95% CI: 0.945ā0.986) (normal value <60 IU/L), respectively, had the best sensitivity (97.1%) and high NPVs (99.6%) for exclusion of PEP. Conclusion: Measurements of serum amylase and lipase 2- and 4-h post-ERCP might be useful in prediction of PEP.
- Open Access
- 1 January 2018
- Published byĀ Wolters Kluwer HealthĀ inĀ Advanced Biomedical Research
- Vol.Ā 7 Ā (1) , 55
Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial
Background: This study evaluated the clinical efficacy and tolerability of a 14-day course of bismuth-based quadruple therapy including tinidazole and levofloxacin in compare to a 14-day bismuth-based quadruple therapy including clarithromycin as first-line treatment for Helicobacter pylori infection in Iranian adults. Materials and Methods: The study was a prospective, parallel group, randomized controlled, clinical trial that conducted on 150 patients with H. pylori infection. Patients were randomly assigned to the two groups as follows: first group received pantoprazole 40 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, and clarithromycin 500 mg (PBAC group), and other group received pantoprazole 40 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, tinidazole 500 mg for 7 days, followed by levofloxacin 500 mg for the second 7 days (PBATL group). Main outcomes were eradication rate, tolerance of treatment, and dyspepsia severity. Results: The eradication rates for PBAC regimen was 81.1% (95% confidence interval [CI]: 71.9ā90.2) and for PBATL regimen was 70.8% (95% CI: 60.1ā81.6), which was not significantly different (P = 0.147). Tolerance of treatment was similar between groups. The median of severity of dyspeptic after treatment in PBAC group was 10 [9ā14.75], which was similar to PBATL group 10 [9ā13.5] (P = 0.690). Conclusion: There is no significant difference between PBAC and PBATL regimen, and efficacy was similar in both groups. The overall rate of treatment failure suggests that up to 18%ā30% of patients will fail bismuth-based quadruple therapy and require retreatment for the infection.
- 1 January 2018
- Published byĀ Wolters Kluwer HealthĀ inĀ Advanced Biomedical Research
- Vol.Ā 7 Ā (1) , 55
Open AccessLevofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial
Background: This study evaluated the clinical efficacy and tolerability of a 14-day course of bismuth-based quadruple therapy including tinidazole and levofloxacin in compare to a 14-day bismuth-based quadruple therapy including clarithromycin as first-line treatment for Helicobacter pylori infection in Iranian adults. Materials and Methods: The study was a prospective, parallel group, randomized controlled, clinical trial that conducted on 150 patients with H. pylori infection. Patients were randomly assigned to the two groups as follows: first group received pantoprazole 40 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, and clarithromycin 500 mg (PBAC group), and other group received pantoprazole 40 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, tinidazole 500 mg for 7 days, followed by levofloxacin 500 mg for the second 7 days (PBATL group). Main outcomes were eradication rate, tolerance of treatment, and dyspepsia severity. Results: The eradication rates for PBAC regimen was 81.1% (95% confidence interval [CI]: 71.9ā90.2) and for PBATL regimen was 70.8% (95% CI: 60.1ā81.6), which was not significantly different (P = 0.147). Tolerance of treatment was similar between groups. The median of severity of dyspeptic after treatment in PBAC group was 10 [9ā14.75], which was similar to PBATL group 10 [9ā13.5] (P = 0.690). Conclusion: There is no significant difference between PBAC and PBATL regimen, and efficacy was similar in both groups. The overall rate of treatment failure suggests that up to 18%ā30% of patients will fail bismuth-based quadruple therapy and require retreatment for the infection.
- 24 March 2017
- Published byĀ WileyĀ inĀ Journal of Gastroenterology and Hepatology
- Vol.Ā 32 Ā (4) , 789-796
Etiology and outcome in patients with upper gastrointestinal bleeding: Study on 4747 patients in the central region of Iran
Background and Aim: Upper gastrointestinal bleeding (UGIB) is a threatening condition leading to urgent hospitalization. This study aims to investigate etiology and outcome in UGIB patients in Iran.Methods: Medical records of GIB patients admitted to Alzahra referral hospital (in Isfahan) during 2010ā2015 were retrospectively reviewed for demographic data, comorbidities, history of smoking and taking nonāsteroidal antiāinflammatory drugs (NSAIDs), presenting symptoms, endoscopic findings, therapeutic endoscopy, blood products' infusion, surgical intervention, rebleeding, and mortality.Results: A total of 4747 patients were enrolled in the study (69.2% men, mean age = 55.46 ± 21.98 years). Hematemesis was the most frequent presenting symptom (63.5%). Peptic ulcer (duodenal ulcer in most cases) was seen as the main reason for UGIB (42.4%). Rebleeding (present in 16.5% of patients) was found to be more frequent in patients with older age, presenting sign of hematochezia and hypotension, history of taking NSAIDs and smoking, presence of comorbidities, history of bleeding because of UGI tract neoplasm and esophageal varices, history of needing blood products' infusion, and history of therapeutic endoscopy or surgical intervention (P < 0.005). We found that mortality (5.5% in total) was also higher in the same group of patients that were seen to have a higher tendency for rebleeding (P < 0.005).Conclusion: Peptic ulcers are the most common cause of UGIB. Comorbidities, hemodynamic instability, highārisk endoscopic stigmata, history of smoking and taking NSAIDs, gastric and esophageal malignancies, may be important predisposing factors for rebleeding and mortality in patients with UGIB.
- 24 March 2017
- Published byĀ WileyĀ inĀ Journal of Gastroenterology and Hepatology
- Vol.Ā 32 Ā (4) , 789-796
Etiology and outcome in patients with upper gastrointestinal bleeding: Study on 4747 patients in the central region of Iran
Background and Aim: Upper gastrointestinal bleeding (UGIB) is a threatening condition leading to urgent hospitalization. This study aims to investigate etiology and outcome in UGIB patients in Iran.Methods: Medical records of GIB patients admitted to Alzahra referral hospital (in Isfahan) during 2010ā2015 were retrospectively reviewed for demographic data, comorbidities, history of smoking and taking nonāsteroidal antiāinflammatory drugs (NSAIDs), presenting symptoms, endoscopic findings, therapeutic endoscopy, blood products' infusion, surgical intervention, rebleeding, and mortality.Results: A total of 4747 patients were enrolled in the study (69.2% men, mean age = 55.46 ± 21.98 years). Hematemesis was the most frequent presenting symptom (63.5%). Peptic ulcer (duodenal ulcer in most cases) was seen as the main reason for UGIB (42.4%). Rebleeding (present in 16.5% of patients) was found to be more frequent in patients with older age, presenting sign of hematochezia and hypotension, history of taking NSAIDs and smoking, presence of comorbidities, history of bleeding because of UGI tract neoplasm and esophageal varices, history of needing blood products' infusion, and history of therapeutic endoscopy or surgical intervention (P < 0.005). We found that mortality (5.5% in total) was also higher in the same group of patients that were seen to have a higher tendency for rebleeding (P < 0.005).Conclusion: Peptic ulcers are the most common cause of UGIB. Comorbidities, hemodynamic instability, highārisk endoscopic stigmata, history of smoking and taking NSAIDs, gastric and esophageal malignancies, may be important predisposing factors for rebleeding and mortality in patients with UGIB.
- Open Access
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Advanced Biomedical Research
- Vol.Ā 6 Ā (1) , 120
Efficacy Comparison of Divided and Infusion Intravenous Pantoprazole Methods after Endoscopic Therapy in Patients with Acute Gastrointestinal Bleeding
Background: Intravenous pantoprazole administration in patients with severe bleeding under urgent endoscopic therapy is effective. Furthermore, its infusion dose is useful to control bleeding; however, it is not economical. In this study, clinical outcomes and intravenous infusion of pantoprazole after endoscopic therapy plus efficacy of infusion dosage and divided doses are compared. Materials and Methods: This prospective, comparative study conducted on 18 adult (>18 years) patients referred to Al Zahra Hospital for hematemesis and melena bleeding who underwent endoscopic treatment with pantoprazole which divided into two groups of forty patients. First group received intravenous infusion for 80 mg and 8 mg/h. The second group received intravenous infusion with divided doses as 40 mg twice daily for 3 days. Clinical outcomes such as rebleeding, duration of hospitalization, amount of blood transfused, and mortality within 3 days after endoscopic treatment were collected and analyzed by SPSS software (version 20) using independent t-test, Chi-square test, and Fisher's exact test. Results: Duration of hospitalization in the pantoprazole infusion group was 5.42 ± 4.62 days, with three patients (7.5%) having rebleeding, and in the divided pantoprazole group was 5.90 ± 3.08 days, with four patients (10%) having rebleeding, and overall, only one person died in the divided pantoprazole group (2.5%) out of eighty patients. No significant difference was observed between two groups in terms of clinical outcomes (P > 0.05). Conclusion: Regarding to results, it can be stated that both methods with specified dosage had significant impact on improvement of hematemesis and melena. Furthermore, due to lower costs, low dose of pantoprazole in divided approach as 40 mg/12 h is proposed.
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Advanced Biomedical Research
- Vol.Ā 6 Ā (1) , 120
Open AccessEfficacy Comparison of Divided and Infusion Intravenous Pantoprazole Methods after Endoscopic Therapy in Patients with Acute Gastrointestinal Bleeding
Background: Intravenous pantoprazole administration in patients with severe bleeding under urgent endoscopic therapy is effective. Furthermore, its infusion dose is useful to control bleeding; however, it is not economical. In this study, clinical outcomes and intravenous infusion of pantoprazole after endoscopic therapy plus efficacy of infusion dosage and divided doses are compared. Materials and Methods: This prospective, comparative study conducted on 18 adult (>18 years) patients referred to Al Zahra Hospital for hematemesis and melena bleeding who underwent endoscopic treatment with pantoprazole which divided into two groups of forty patients. First group received intravenous infusion for 80 mg and 8 mg/h. The second group received intravenous infusion with divided doses as 40 mg twice daily for 3 days. Clinical outcomes such as rebleeding, duration of hospitalization, amount of blood transfused, and mortality within 3 days after endoscopic treatment were collected and analyzed by SPSS software (version 20) using independent t-test, Chi-square test, and Fisher's exact test. Results: Duration of hospitalization in the pantoprazole infusion group was 5.42 ± 4.62 days, with three patients (7.5%) having rebleeding, and in the divided pantoprazole group was 5.90 ± 3.08 days, with four patients (10%) having rebleeding, and overall, only one person died in the divided pantoprazole group (2.5%) out of eighty patients. No significant difference was observed between two groups in terms of clinical outcomes (P > 0.05). Conclusion: Regarding to results, it can be stated that both methods with specified dosage had significant impact on improvement of hematemesis and melena. Furthermore, due to lower costs, low dose of pantoprazole in divided approach as 40 mg/12 h is proposed.
- Open Access
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Research in Medical Sciences
- Vol.Ā 22 Ā (1) , 72
Association of irritable bowel syndrome and sleep apnea in patients referred to sleep laboratory
Background: Irritable bowel syndrome (IBS) is assumed as one of the most frequent gastrointestinal disorders, which decreases the patient's quality of life. IBS pathogenesis, however, is not clearly defined. It seems that sleep apnea induces or escalates IBS clinical symptoms. This study aims at evaluating of IBS prevalence in patients, who are afflicted or are not afflicted with sleep apnea. Materials and Methods: This was a caseācontrol study, which was implemented in a sleep laboratory located in Isfahan, Iran. We recruited 200 patients being more than 15 years from 2014 to 2015. Based on the apneaāhypopnea index (AHI), we recruited 100 patients in each of two groups: negative sleep apnea (NSA) (AHI ā¤4) and positive sleep apnea (PSA) (AHI >4). IBS was diagnosed through a Rome III diagnostic questionnaire. Results: Overall, the prevalence of IBS among patients referred to sleep laboratory was 17.6%. Indeed, IBS prevalence in NSA and PSA groups were 8.2% and 27.1%, respectively. Furthermore, odds ratio of IBS in PSA group versus NSA was 3.92 (95% confidence interval = 1.58ā9.77, P = 0.003). Our results showed that the prevalence of IBS did not differ significantly between various severity of sleep apnea (P = 0.452). Conclusion: This study showed that there was a positive association between sleep apnea and IBS.
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Research in Medical Sciences
- Vol.Ā 22 Ā (1) , 72
Open AccessAssociation of irritable bowel syndrome and sleep apnea in patients referred to sleep laboratory
Background: Irritable bowel syndrome (IBS) is assumed as one of the most frequent gastrointestinal disorders, which decreases the patient's quality of life. IBS pathogenesis, however, is not clearly defined. It seems that sleep apnea induces or escalates IBS clinical symptoms. This study aims at evaluating of IBS prevalence in patients, who are afflicted or are not afflicted with sleep apnea. Materials and Methods: This was a caseācontrol study, which was implemented in a sleep laboratory located in Isfahan, Iran. We recruited 200 patients being more than 15 years from 2014 to 2015. Based on the apneaāhypopnea index (AHI), we recruited 100 patients in each of two groups: negative sleep apnea (NSA) (AHI ā¤4) and positive sleep apnea (PSA) (AHI >4). IBS was diagnosed through a Rome III diagnostic questionnaire. Results: Overall, the prevalence of IBS among patients referred to sleep laboratory was 17.6%. Indeed, IBS prevalence in NSA and PSA groups were 8.2% and 27.1%, respectively. Furthermore, odds ratio of IBS in PSA group versus NSA was 3.92 (95% confidence interval = 1.58ā9.77, P = 0.003). Our results showed that the prevalence of IBS did not differ significantly between various severity of sleep apnea (P = 0.452). Conclusion: This study showed that there was a positive association between sleep apnea and IBS.
- Open Access
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Advanced Biomedical Research
- Vol.Ā 6 Ā (1) , 81
The Relationship between the Time of Endoscopy and Morbidity and Mortality Rates in Patients with Upper Gastrointestinal Bleeding
Background: This study was done to evaluate the relationship between the time of endoscopy in patients with upper gastrointestinal bleeding with morbidity and mortality rates of patients at the Al Zahra Hospital emergency room. Materials and Methods: In a cohort study, 1152 patients at 2014 and 2015 have been hospitalized due to gastrointestinal bleeding in Al Zahra Hospital, were selected and demographic and clinical information and day and time of endoscopy and hospital mortality and fewer deaths than a month after discharge were studied, and prognosis was analyzed in terms of day and time of endoscopy. Results: Nine hundred and seventy-three cases (84.5%) of endoscopy were performed during the working days and 179 (15.5%) were performed on holidays. Moreover, 801 cases (69.5%) of endoscopy were done in the morning and 351 cases (30.5%) were performed in the evening and night shifts. The day and time of endoscopy had no significant effect on mortality in hospital and less than a month after but hospital death in whom underwent endoscopy by fellowship was significantly higher (P = 0.004). Conclusion: Endoscopy in nonholiday and holiday days and the time of endoscopy has no significant effect on hospital mortality 1 month after discharge. However, other factors such as endoscopy by attendant or fellowship, time between admission to endoscopy, age and sex of the patients, etc., were significantly effective on in-hospital mortality and death 1 months after discharge. Also faster and sooner endoscopy cannot reduce rate of blood transfusions or reduce the length of hospital stay but faster endoscopy of patients can reduce the risk of in-hospital death.
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Advanced Biomedical Research
- Vol.Ā 6 Ā (1) , 81
Open AccessThe Relationship between the Time of Endoscopy and Morbidity and Mortality Rates in Patients with Upper Gastrointestinal Bleeding
Background: This study was done to evaluate the relationship between the time of endoscopy in patients with upper gastrointestinal bleeding with morbidity and mortality rates of patients at the Al Zahra Hospital emergency room. Materials and Methods: In a cohort study, 1152 patients at 2014 and 2015 have been hospitalized due to gastrointestinal bleeding in Al Zahra Hospital, were selected and demographic and clinical information and day and time of endoscopy and hospital mortality and fewer deaths than a month after discharge were studied, and prognosis was analyzed in terms of day and time of endoscopy. Results: Nine hundred and seventy-three cases (84.5%) of endoscopy were performed during the working days and 179 (15.5%) were performed on holidays. Moreover, 801 cases (69.5%) of endoscopy were done in the morning and 351 cases (30.5%) were performed in the evening and night shifts. The day and time of endoscopy had no significant effect on mortality in hospital and less than a month after but hospital death in whom underwent endoscopy by fellowship was significantly higher (P = 0.004). Conclusion: Endoscopy in nonholiday and holiday days and the time of endoscopy has no significant effect on hospital mortality 1 month after discharge. However, other factors such as endoscopy by attendant or fellowship, time between admission to endoscopy, age and sex of the patients, etc., were significantly effective on in-hospital mortality and death 1 months after discharge. Also faster and sooner endoscopy cannot reduce rate of blood transfusions or reduce the length of hospital stay but faster endoscopy of patients can reduce the risk of in-hospital death.
- Open Access
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Advanced Biomedical Research
- Vol.Ā 6 Ā (1) , 77
Polymorphism (rs16917496) at the miR-502 Binding Site of the Lysine Methyltransferase 5A (SET8) and Its Correlation with Colorectal Cancer in Iranians
Background: One of the gene expression regulatory mechanisms is mediated by small noncoding RNAs called microRNA (miRNA). They interact with a recognition sequence located mostly in 3ā-untranslated regions (3ā-UTRs) of mRNAs. Polymorphisms in miRNAs recognition sequences could affect gene expression which in turn may alter disease susceptibility. SET8, a member of the SET domain-containing methyltransferase, acts in a variety of biological processes such as genomic stability. Here, we report correlation of rs16917496 polymorphism, located in the recognition sequence of miR-502 within 3ā-UTR of SET8, with colorectal cancer (CRC) in Iranians. Materials and Methods: One hundred and seventy CRC patients and 170 noncancer counterparts were recruited in this caseācontrol study. Genotyping of rs16917496 was performed using polymerase chain reaction-restriction fragment length polymorphism method. Results: There was no significant association of rs16917496 with CRC in population under study (P value for genotype and allele distribution were >0.05). However, stratification analysis based on smoking status revealed that TT+TC genotypes of SET8 rs16917496 are strongly associated with increased risk of CRC (odds ratio: 5.8, 95% confidence interval: 1.37ā24.34, P - 0.005) in smoker subgroup. Conclusion: Correlation of rs16917496 T allele with CRC in smokers is emphasizing the importance of individualsā genotype in the recruitment of adverse health hazards of smoking more profoundly for certain people compared to others.
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Advanced Biomedical Research
- Vol.Ā 6 Ā (1) , 77
Open AccessPolymorphism (rs16917496) at the miR-502 Binding Site of the Lysine Methyltransferase 5A (SET8) and Its Correlation with Colorectal Cancer in Iranians
Background: One of the gene expression regulatory mechanisms is mediated by small noncoding RNAs called microRNA (miRNA). They interact with a recognition sequence located mostly in 3ā-untranslated regions (3ā-UTRs) of mRNAs. Polymorphisms in miRNAs recognition sequences could affect gene expression which in turn may alter disease susceptibility. SET8, a member of the SET domain-containing methyltransferase, acts in a variety of biological processes such as genomic stability. Here, we report correlation of rs16917496 polymorphism, located in the recognition sequence of miR-502 within 3ā-UTR of SET8, with colorectal cancer (CRC) in Iranians. Materials and Methods: One hundred and seventy CRC patients and 170 noncancer counterparts were recruited in this caseācontrol study. Genotyping of rs16917496 was performed using polymerase chain reaction-restriction fragment length polymorphism method. Results: There was no significant association of rs16917496 with CRC in population under study (P value for genotype and allele distribution were >0.05). However, stratification analysis based on smoking status revealed that TT+TC genotypes of SET8 rs16917496 are strongly associated with increased risk of CRC (odds ratio: 5.8, 95% confidence interval: 1.37ā24.34, P - 0.005) in smoker subgroup. Conclusion: Correlation of rs16917496 T allele with CRC in smokers is emphasizing the importance of individualsā genotype in the recruitment of adverse health hazards of smoking more profoundly for certain people compared to others.
- Open Access
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Research in Medical Sciences
- Vol.Ā 22 Ā (1) , 133
Premedication with benzodiazepines for upper gastrointestinal endoscopy: Comparison between oral midazolam and sublingual alprazolam
Background: Premedication with orally administered benzodiazepines is effective in reducing anxiety and discomfort related to endoscopic procedures. We evaluated the efficacy and safety of oral midazolam in comparison to sublingual alprazolam as premedication for esophagogastroduodenoscopy (EGD). Materials and Methods: Adult candidates for diagnostic EGD received either oral midazolam (7.5 mg in 15 cc apple juice) or sublingual alprazolam (0.5 mg) 30 min before EGD. Procedural anxiety and pain/discomfort were assessed using 11-point numerical rating scales. Patientsā overall tolerance (using a four-point Likert scale) and willingness to repeat the EGD, if necessary, were also assessed. Blood pressure, heart rate, and arterial oxygen saturation were monitored from medication to 30 min after the procedure. Results: Patients experienced a similar reduction in procedural anxiety after medication with oral midazolam and sublingual alprazolam; mean (standard deviation [SD] of 1.86 [1.63] and 2.02 [1.99] points, respectively, P = 0.91). Compared to oral midazolam, pain/discomfort scores were lower with sublingual alprazolam; mean (SD) of 4.80 (3.01) versus 3.68 (3.28), P = 0.024. There was no significant difference between the two groups in patientsā tolerance, willingness to repeat the procedure, or hemodynamic events. Conclusion: Oral midazolam and sublingual alprazolam are equally effective in reducing EGD-related anxiety; however, EGD-related pain/discomfort is lower with alprazolam. Both benzodiazepines are equally safe and can be used as premedication for patients undergoing diagnostic EGD.
- 1 January 2017
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Research in Medical Sciences
- Vol.Ā 22 Ā (1) , 133
Open AccessPremedication with benzodiazepines for upper gastrointestinal endoscopy: Comparison between oral midazolam and sublingual alprazolam
Background: Premedication with orally administered benzodiazepines is effective in reducing anxiety and discomfort related to endoscopic procedures. We evaluated the efficacy and safety of oral midazolam in comparison to sublingual alprazolam as premedication for esophagogastroduodenoscopy (EGD). Materials and Methods: Adult candidates for diagnostic EGD received either oral midazolam (7.5 mg in 15 cc apple juice) or sublingual alprazolam (0.5 mg) 30 min before EGD. Procedural anxiety and pain/discomfort were assessed using 11-point numerical rating scales. Patientsā overall tolerance (using a four-point Likert scale) and willingness to repeat the EGD, if necessary, were also assessed. Blood pressure, heart rate, and arterial oxygen saturation were monitored from medication to 30 min after the procedure. Results: Patients experienced a similar reduction in procedural anxiety after medication with oral midazolam and sublingual alprazolam; mean (standard deviation [SD] of 1.86 [1.63] and 2.02 [1.99] points, respectively, P = 0.91). Compared to oral midazolam, pain/discomfort scores were lower with sublingual alprazolam; mean (SD) of 4.80 (3.01) versus 3.68 (3.28), P = 0.024. There was no significant difference between the two groups in patientsā tolerance, willingness to repeat the procedure, or hemodynamic events. Conclusion: Oral midazolam and sublingual alprazolam are equally effective in reducing EGD-related anxiety; however, EGD-related pain/discomfort is lower with alprazolam. Both benzodiazepines are equally safe and can be used as premedication for patients undergoing diagnostic EGD.